The board of directors of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. announced that the shareholders of the company and potential investors that based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2017, the Board expects to record a decrease in revenue for LIBOd® one major product of the Group, by approximately 50% for the year ended 31 December 2017 as compared to that for the year ended 31 December 2016, and thus a decrease in revenue of the Group by approximately 20% for the year ended 31 December 2017 accordingly; and the board expects to record a decrease in net profit of the Group by approximately 50% for the year ended 31 December 2017 as compared to that for the year ended 31 December 2016. Together with the increase of R&D costs, the net profit of the Group would be further decreased.